Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Hematology and Oncology Specialists, New Orleans, LA, United States

Survival: 5.4 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: New Orleans, LA
Hospital: Hematology and Oncology Specialists
Journal: Link
Date: 2/2015

This phase 2 study involved 34 human epidermal growth factor receptor 2epositive (HER2+) metastatic breast cancer patients who had received prior treatment with trastuzumab. The median patient age was 55 years and all were female.

Patients received biologic therapy with ridaforolimus, an mTOR inhibitor, and trastuzumab, an antibody that inhibits the HER2 receptor.

There was one treatment-related death due to bowel perforation. Grade 3-4 stomatitis (inflammation of mouth and lips), leucopenia, and neutropenia were also reported.

The median overall survival was 5.4 months.

This study was supported by ARIAD Pharmaceuticals, Inc.

Correspondence: Dr. Milton Seiler; email:

E-mail to a Friend Email Physician More Information